Jiangsu Hengrui Pharmaceuticals Entangled in Legal Disputes with BeyondSpring and Reistone
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) is currently entangled in legal challenges involving...
Reistone Biopharma
Reistone Biopharma’s Ivarmacitinib Accepted for Review by China’s CDE for Atopic Dermatitis
Reistone Biopharma Co., Ltd, a company incubated by Hengrui Pharmaceuticals (SHA: 600276) with an investment...
Reistone Biopharma’s Edralbrutinib Earns Orphan Drug Designation for NMOSD from US FDA
Reistone Biopharma Co., Ltd, a company incubated by Hengrui Medicine with an investment of USD...
Reistone Biopharma’s RSS0343 Receives NMPA Approval for Non-Cystic Fibrosis Bronchiectasis
Reistone Biopharma Co., Ltd, a company incubated by Hengrui Pharmaceuticals (SHA: 600276) with an investment...
Reistone Biopharma’s Ivarmacitinib Shows Positive Results in Phase III QUARTZ3 Study
Reistone Biopharma Co., Ltd, incubated by Hengrui Pharmaceuticals (SHA: 600276) with USD 100 million in...